nodes	percent_of_prediction	percent_of_DWPC	metapath
Nadolol—Respiratory distress—Fludarabine—lymphatic system cancer	0.0283	0.0283	CcSEcCtD
Nadolol—Arterial thrombosis—Methotrexate—lymphatic system cancer	0.0198	0.0198	CcSEcCtD
Nadolol—Respiratory distress—Vincristine—lymphatic system cancer	0.0173	0.0173	CcSEcCtD
Nadolol—Depression—Mechlorethamine—lymphatic system cancer	0.0155	0.0155	CcSEcCtD
Nadolol—Sleep disorder—Fludarabine—lymphatic system cancer	0.0151	0.0151	CcSEcCtD
Nadolol—Agranulocytosis—Mechlorethamine—lymphatic system cancer	0.0145	0.0145	CcSEcCtD
Nadolol—Cardiac failure congestive—Fludarabine—lymphatic system cancer	0.0144	0.0144	CcSEcCtD
Nadolol—Visual disturbance—Fludarabine—lymphatic system cancer	0.0138	0.0138	CcSEcCtD
Nadolol—Cardiac failure—Fludarabine—lymphatic system cancer	0.0134	0.0134	CcSEcCtD
Nadolol—Tinnitus—Mechlorethamine—lymphatic system cancer	0.013	0.013	CcSEcCtD
Nadolol—Bronchospasm—Teniposide—lymphatic system cancer	0.0126	0.0126	CcSEcCtD
Nadolol—Alopecia—Mechlorethamine—lymphatic system cancer	0.0123	0.0123	CcSEcCtD
Nadolol—Hepatic enzyme increased—Mitoxantrone—lymphatic system cancer	0.0113	0.0113	CcSEcCtD
Nadolol—Sweating—Teniposide—lymphatic system cancer	0.011	0.011	CcSEcCtD
Nadolol—Disorientation—Bleomycin—lymphatic system cancer	0.0107	0.0107	CcSEcCtD
Nadolol—Anorexia—Mechlorethamine—lymphatic system cancer	0.00945	0.00945	CcSEcCtD
Nadolol—Alopecia—Teniposide—lymphatic system cancer	0.00909	0.00909	CcSEcCtD
Nadolol—Amnesia—Carmustine—lymphatic system cancer	0.0089	0.0089	CcSEcCtD
Nadolol—Visual impairment—Fludarabine—lymphatic system cancer	0.00871	0.00871	CcSEcCtD
Nadolol—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00862	0.00862	CcSEcCtD
Nadolol—Cardiac failure congestive—Mitoxantrone—lymphatic system cancer	0.00858	0.00858	CcSEcCtD
Nadolol—Diplopia—Carmustine—lymphatic system cancer	0.00837	0.00837	CcSEcCtD
Nadolol—Bronchospasm—Bleomycin—lymphatic system cancer	0.00815	0.00815	CcSEcCtD
Nadolol—Alopecia—Fludarabine—lymphatic system cancer	0.00799	0.00799	CcSEcCtD
Nadolol—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.00797	0.00797	CcSEcCtD
Nadolol—Hypertension—Teniposide—lymphatic system cancer	0.00773	0.00773	CcSEcCtD
Nadolol—Chest pain—Teniposide—lymphatic system cancer	0.00763	0.00763	CcSEcCtD
Nadolol—Oedema—Teniposide—lymphatic system cancer	0.00731	0.00731	CcSEcCtD
Nadolol—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00707	0.00707	CcSEcCtD
Nadolol—Pruritus—Mechlorethamine—lymphatic system cancer	0.00702	0.00702	CcSEcCtD
Nadolol—Anorexia—Teniposide—lymphatic system cancer	0.00697	0.00697	CcSEcCtD
Nadolol—Cough—Fludarabine—lymphatic system cancer	0.00687	0.00687	CcSEcCtD
Nadolol—Hypotension—Teniposide—lymphatic system cancer	0.00683	0.00683	CcSEcCtD
Nadolol—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00678	0.00678	CcSEcCtD
Nadolol—Dyspnoea—Teniposide—lymphatic system cancer	0.00652	0.00652	CcSEcCtD
Nadolol—Depression—Carmustine—lymphatic system cancer	0.00643	0.00643	CcSEcCtD
Nadolol—Oedema—Fludarabine—lymphatic system cancer	0.00642	0.00642	CcSEcCtD
Nadolol—Erectile dysfunction—Vincristine—lymphatic system cancer	0.00636	0.00636	CcSEcCtD
Nadolol—Decreased appetite—Teniposide—lymphatic system cancer	0.00635	0.00635	CcSEcCtD
Nadolol—Vomiting—Mechlorethamine—lymphatic system cancer	0.0063	0.0063	CcSEcCtD
Nadolol—Rash—Mechlorethamine—lymphatic system cancer	0.00625	0.00625	CcSEcCtD
Nadolol—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00625	0.00625	CcSEcCtD
Nadolol—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00621	0.00621	CcSEcCtD
Nadolol—Erectile dysfunction—Mitoxantrone—lymphatic system cancer	0.00619	0.00619	CcSEcCtD
Nadolol—Depression—Vincristine—lymphatic system cancer	0.00614	0.00614	CcSEcCtD
Nadolol—Anorexia—Fludarabine—lymphatic system cancer	0.00612	0.00612	CcSEcCtD
Nadolol—Weight increased—Mitoxantrone—lymphatic system cancer	0.00612	0.00612	CcSEcCtD
Nadolol—Sweating—Vincristine—lymphatic system cancer	0.0059	0.0059	CcSEcCtD
Nadolol—Nausea—Mechlorethamine—lymphatic system cancer	0.00589	0.00589	CcSEcCtD
Nadolol—Alopecia—Bleomycin—lymphatic system cancer	0.00586	0.00586	CcSEcCtD
Nadolol—Conjunctivitis—Mitoxantrone—lymphatic system cancer	0.00583	0.00583	CcSEcCtD
Nadolol—Body temperature increased—Teniposide—lymphatic system cancer	0.00578	0.00578	CcSEcCtD
Nadolol—Paraesthesia—Fludarabine—lymphatic system cancer	0.00577	0.00577	CcSEcCtD
Nadolol—Hallucination—Carmustine—lymphatic system cancer	0.00576	0.00576	CcSEcCtD
Nadolol—Sweating—Mitoxantrone—lymphatic system cancer	0.00575	0.00575	CcSEcCtD
Nadolol—Dyspnoea—Fludarabine—lymphatic system cancer	0.00573	0.00573	CcSEcCtD
Nadolol—Dyspepsia—Fludarabine—lymphatic system cancer	0.00566	0.00566	CcSEcCtD
Nadolol—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00564	0.00564	CcSEcCtD
Nadolol—Dysarthria—Methotrexate—lymphatic system cancer	0.00564	0.00564	CcSEcCtD
Nadolol—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00559	0.00559	CcSEcCtD
Nadolol—Decreased appetite—Fludarabine—lymphatic system cancer	0.00558	0.00558	CcSEcCtD
Nadolol—Visual impairment—Carmustine—lymphatic system cancer	0.00558	0.00558	CcSEcCtD
Nadolol—Fatigue—Fludarabine—lymphatic system cancer	0.00554	0.00554	CcSEcCtD
Nadolol—Hallucination—Vincristine—lymphatic system cancer	0.0055	0.0055	CcSEcCtD
Nadolol—Pain—Fludarabine—lymphatic system cancer	0.00549	0.00549	CcSEcCtD
Nadolol—Constipation—Fludarabine—lymphatic system cancer	0.00549	0.00549	CcSEcCtD
Nadolol—Bradycardia—Mitoxantrone—lymphatic system cancer	0.00548	0.00548	CcSEcCtD
Nadolol—Asthenia—Teniposide—lymphatic system cancer	0.00524	0.00524	CcSEcCtD
Nadolol—Pruritus—Teniposide—lymphatic system cancer	0.00517	0.00517	CcSEcCtD
Nadolol—Alopecia—Carmustine—lymphatic system cancer	0.00511	0.00511	CcSEcCtD
Nadolol—Body temperature increased—Fludarabine—lymphatic system cancer	0.00508	0.00508	CcSEcCtD
Nadolol—Cough—Bleomycin—lymphatic system cancer	0.00504	0.00504	CcSEcCtD
Nadolol—Diarrhoea—Teniposide—lymphatic system cancer	0.005	0.005	CcSEcCtD
Nadolol—Chest pain—Bleomycin—lymphatic system cancer	0.00491	0.00491	CcSEcCtD
Nadolol—Alopecia—Vincristine—lymphatic system cancer	0.00488	0.00488	CcSEcCtD
Nadolol—Alopecia—Mitoxantrone—lymphatic system cancer	0.00475	0.00475	CcSEcCtD
Nadolol—Pulmonary oedema—Methotrexate—lymphatic system cancer	0.00475	0.00475	CcSEcCtD
Nadolol—Vision blurred—Carmustine—lymphatic system cancer	0.00475	0.00475	CcSEcCtD
Nadolol—Oedema—Bleomycin—lymphatic system cancer	0.00471	0.00471	CcSEcCtD
Nadolol—Vomiting—Teniposide—lymphatic system cancer	0.00465	0.00465	CcSEcCtD
Nadolol—Asthenia—Fludarabine—lymphatic system cancer	0.00461	0.00461	CcSEcCtD
Nadolol—Rash—Teniposide—lymphatic system cancer	0.00461	0.00461	CcSEcCtD
Nadolol—Dermatitis—Teniposide—lymphatic system cancer	0.0046	0.0046	CcSEcCtD
Nadolol—Pruritus—Fludarabine—lymphatic system cancer	0.00455	0.00455	CcSEcCtD
Nadolol—Anorexia—Bleomycin—lymphatic system cancer	0.00449	0.00449	CcSEcCtD
Nadolol—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00441	0.00441	CcSEcCtD
Nadolol—Hypotension—Bleomycin—lymphatic system cancer	0.0044	0.0044	CcSEcCtD
Nadolol—Diarrhoea—Fludarabine—lymphatic system cancer	0.0044	0.0044	CcSEcCtD
Nadolol—Hypertension—Carmustine—lymphatic system cancer	0.00435	0.00435	CcSEcCtD
Nadolol—Nausea—Teniposide—lymphatic system cancer	0.00434	0.00434	CcSEcCtD
Nadolol—Chest pain—Carmustine—lymphatic system cancer	0.00429	0.00429	CcSEcCtD
Nadolol—Paraesthesia—Bleomycin—lymphatic system cancer	0.00423	0.00423	CcSEcCtD
Nadolol—Dyspnoea—Bleomycin—lymphatic system cancer	0.0042	0.0042	CcSEcCtD
Nadolol—Hypertension—Vincristine—lymphatic system cancer	0.00415	0.00415	CcSEcCtD
Nadolol—Oedema—Carmustine—lymphatic system cancer	0.00411	0.00411	CcSEcCtD
Nadolol—Decreased appetite—Bleomycin—lymphatic system cancer	0.00409	0.00409	CcSEcCtD
Nadolol—Visual disturbance—Methotrexate—lymphatic system cancer	0.00409	0.00409	CcSEcCtD
Nadolol—Cough—Mitoxantrone—lymphatic system cancer	0.00409	0.00409	CcSEcCtD
Nadolol—Vomiting—Fludarabine—lymphatic system cancer	0.00408	0.00408	CcSEcCtD
Nadolol—Rash—Fludarabine—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Nadolol—Dermatitis—Fludarabine—lymphatic system cancer	0.00405	0.00405	CcSEcCtD
Nadolol—Hypertension—Mitoxantrone—lymphatic system cancer	0.00404	0.00404	CcSEcCtD
Nadolol—Pain—Bleomycin—lymphatic system cancer	0.00403	0.00403	CcSEcCtD
Nadolol—Chest pain—Mitoxantrone—lymphatic system cancer	0.00399	0.00399	CcSEcCtD
Nadolol—Lethargy—Methotrexate—lymphatic system cancer	0.00395	0.00395	CcSEcCtD
Nadolol—Oedema—Vincristine—lymphatic system cancer	0.00393	0.00393	CcSEcCtD
Nadolol—Anorexia—Carmustine—lymphatic system cancer	0.00392	0.00392	CcSEcCtD
Nadolol—Hypotension—Carmustine—lymphatic system cancer	0.00384	0.00384	CcSEcCtD
Nadolol—Oedema—Mitoxantrone—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Nadolol—Nausea—Fludarabine—lymphatic system cancer	0.00382	0.00382	CcSEcCtD
Nadolol—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Nadolol—Shock—Mitoxantrone—lymphatic system cancer	0.00376	0.00376	CcSEcCtD
Nadolol—Anorexia—Vincristine—lymphatic system cancer	0.00374	0.00374	CcSEcCtD
Nadolol—Body temperature increased—Bleomycin—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Nadolol—Insomnia—Carmustine—lymphatic system cancer	0.00372	0.00372	CcSEcCtD
Nadolol—Irritability—Methotrexate—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Nadolol—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.0037	0.0037	CcSEcCtD
Nadolol—Paraesthesia—Carmustine—lymphatic system cancer	0.00369	0.00369	CcSEcCtD
Nadolol—Mood swings—Methotrexate—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Nadolol—Hypotension—Vincristine—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Nadolol—Dyspnoea—Carmustine—lymphatic system cancer	0.00367	0.00367	CcSEcCtD
Nadolol—Anorexia—Mitoxantrone—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Nadolol—Decreased appetite—Carmustine—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Nadolol—Hypotension—Mitoxantrone—lymphatic system cancer	0.00357	0.00357	CcSEcCtD
Nadolol—Insomnia—Vincristine—lymphatic system cancer	0.00355	0.00355	CcSEcCtD
Nadolol—Paraesthesia—Vincristine—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Nadolol—Constipation—Carmustine—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Nadolol—Pain—Carmustine—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Nadolol—Paraesthesia—Mitoxantrone—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Nadolol—Decreased appetite—Vincristine—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Nadolol—Dyspnoea—Mitoxantrone—lymphatic system cancer	0.00341	0.00341	CcSEcCtD
Nadolol—Fatigue—Vincristine—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Nadolol—Asthenia—Bleomycin—lymphatic system cancer	0.00338	0.00338	CcSEcCtD
Nadolol—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Nadolol—Constipation—Vincristine—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Nadolol—Pain—Vincristine—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Nadolol—Pruritus—Bleomycin—lymphatic system cancer	0.00333	0.00333	CcSEcCtD
Nadolol—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Nadolol—Fatigue—Mitoxantrone—lymphatic system cancer	0.0033	0.0033	CcSEcCtD
Nadolol—Pain—Mitoxantrone—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Nadolol—Constipation—Mitoxantrone—lymphatic system cancer	0.00327	0.00327	CcSEcCtD
Nadolol—Body temperature increased—Carmustine—lymphatic system cancer	0.00325	0.00325	CcSEcCtD
Nadolol—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Nadolol—Body temperature increased—Vincristine—lymphatic system cancer	0.0031	0.0031	CcSEcCtD
Nadolol—Erectile dysfunction—Methotrexate—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Nadolol—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00302	0.00302	CcSEcCtD
Nadolol—Vomiting—Bleomycin—lymphatic system cancer	0.003	0.003	CcSEcCtD
Nadolol—Depression—Methotrexate—lymphatic system cancer	0.00298	0.00298	CcSEcCtD
Nadolol—Rash—Bleomycin—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Nadolol—Dermatitis—Bleomycin—lymphatic system cancer	0.00297	0.00297	CcSEcCtD
Nadolol—Asthenia—Carmustine—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Nadolol—Conjunctivitis—Methotrexate—lymphatic system cancer	0.0029	0.0029	CcSEcCtD
Nadolol—Sweating—Methotrexate—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Nadolol—Asthenia—Vincristine—lymphatic system cancer	0.00282	0.00282	CcSEcCtD
Nadolol—Diarrhoea—Carmustine—lymphatic system cancer	0.00281	0.00281	CcSEcCtD
Nadolol—Nausea—Bleomycin—lymphatic system cancer	0.0028	0.0028	CcSEcCtD
Nadolol—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Nadolol—Asthenia—Mitoxantrone—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Nadolol—Dizziness—Carmustine—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Nadolol—Diarrhoea—Vincristine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Nadolol—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Nadolol—Vomiting—Carmustine—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Nadolol—Dizziness—Vincristine—lymphatic system cancer	0.0026	0.0026	CcSEcCtD
Nadolol—Rash—Carmustine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Nadolol—Dermatitis—Carmustine—lymphatic system cancer	0.00259	0.00259	CcSEcCtD
Nadolol—Visual impairment—Methotrexate—lymphatic system cancer	0.00258	0.00258	CcSEcCtD
Nadolol—Tinnitus—Methotrexate—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Nadolol—Vomiting—Vincristine—lymphatic system cancer	0.0025	0.0025	CcSEcCtD
Nadolol—Rash—Vincristine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Nadolol—Dermatitis—Vincristine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Nadolol—Nausea—Carmustine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Nadolol—Vomiting—Mitoxantrone—lymphatic system cancer	0.00243	0.00243	CcSEcCtD
Nadolol—Rash—Mitoxantrone—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Nadolol—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00241	0.00241	CcSEcCtD
Nadolol—Alopecia—Methotrexate—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Nadolol—Nausea—Vincristine—lymphatic system cancer	0.00233	0.00233	CcSEcCtD
Nadolol—Nausea—Mitoxantrone—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Nadolol—Vision blurred—Methotrexate—lymphatic system cancer	0.0022	0.0022	CcSEcCtD
Nadolol—Cough—Methotrexate—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Nadolol—Chest pain—Methotrexate—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Nadolol—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.00184	0.00184	CcSEcCtD
Nadolol—Anorexia—Methotrexate—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Nadolol—Hypotension—Methotrexate—lymphatic system cancer	0.00178	0.00178	CcSEcCtD
Nadolol—Insomnia—Methotrexate—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Nadolol—Paraesthesia—Methotrexate—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Nadolol—Dyspnoea—Methotrexate—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Nadolol—Dyspepsia—Methotrexate—lymphatic system cancer	0.00168	0.00168	CcSEcCtD
Nadolol—Decreased appetite—Methotrexate—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Nadolol—Fatigue—Methotrexate—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Nadolol—Pain—Methotrexate—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Nadolol—Body temperature increased—Methotrexate—lymphatic system cancer	0.00151	0.00151	CcSEcCtD
Nadolol—Asthenia—Methotrexate—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Nadolol—Pruritus—Methotrexate—lymphatic system cancer	0.00135	0.00135	CcSEcCtD
Nadolol—Diarrhoea—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Nadolol—Dizziness—Methotrexate—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Nadolol—Vomiting—Methotrexate—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Nadolol—Rash—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Nadolol—Dermatitis—Methotrexate—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Nadolol—Nausea—Methotrexate—lymphatic system cancer	0.00113	0.00113	CcSEcCtD
